细胞因子诱导的杀伤细胞/白细胞介素2治疗儿童急性淋巴细胞白血病微小残留病疗效观察  

Treatment of minimal residual disease of childhood acute lymphoblastic leukemia by cytokine-induced killer/interleukin-2

作　　者：张乐萍[1] 陆爱东[1] 童春容[2] 刘桂兰[1] 田开功[1] 陆道培[2] 

机构地区：[1]北京大学人民医院儿科,100044 [2]北京大学人民医院血液病研究所,100044

出　　处：《实用儿科临床杂志》2003年第3期185-186,共2页Journal of Applied Clinical Pediatrics

摘　　要：目的　探讨细胞因子诱导的杀伤细胞 (CIK)及白细胞介素 2 (IL 2 )联合治疗儿童急性淋巴细胞白血病 (ALL)微小残留病 (MRD)的疗效。方法　用巢式PCR法扩增T细胞受体δ(TCRδ)及免疫球蛋白重链(IgH)基因重排检测MRD ,对 2 8例化疗 12个月以上MRD仍阳性者中 14例予CIK细胞 /IL 2输注治疗为治疗组 ,余为对照组。结果　对照组 14例中 8例复发 ,6例MRD转阴 ,并长期生存 ;治疗组MRD均转阴 ,中位随访期 18个月未见复发 (P <0 .0 1)。结论　CIK/IL 2治疗具有清除MRD。Objective To evaluate the efficacy of cytokine induced killer (CIK)cells/interleukin 2(IL 2) on the minimal residual disease(MRD) of childhood acute lymphoblastic leukemia(ALL).Methods The nested polymerase chain reactions with primers for T cell receptor delta and immunoglobulin heavy chain gene were used to test MRD. Twenty eight cases of patients were considered MRD positive after more than 12 months chemotherapy.Fourteen of them were treated with CIK cells/IL 2.The other 14 were compared as control group.Results The 14 cases in the CIK group became MRD negative and none of them was relapsed by 18 month follow up. There was significant difference compared with the relapse rate of control group in which 8 out of 14 were relapsed (P< 0.01) .Conclusion CIK cells/IL 2 immunotherapy can be used to eradicate MRD in childhood ALL.

关 键 词：细胞因子 诱导 杀伤细胞 白细胞介素2 治疗 儿童 急性淋巴细胞白血病 微小残留病 疗效观察 

分 类 号：R733.71[医药卫生—肿瘤]